Does the media favor SINT or NMTC?

In the previous week, Sintx Technologies and Sintx Technologies both had 2 articles in the media. Sintx Technologies' average media sentiment score of 0.93 beat NeuroOne Medical Technologies' score of 0.29 indicating that Sintx Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sintx Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroOne Medical Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CTSO or SINT?

In the previous week, Cytosorbents and Cytosorbents both had 2 articles in the media. Sintx Technologies' average media sentiment score of 0.93 beat Cytosorbents' score of 0.30 indicating that Sintx Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sintx Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SINT or PETV?

Sintx Technologies currently has a consensus target price of $11.00, indicating a potential upside of 391.07%. Given Sintx Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Sintx Technologies is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SINT or PETV more profitable?

PetVivo has a net margin of -902.82% compared to Sintx Technologies' net margin of -1,058.60%. Sintx Technologies' return on equity of -366.49% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets Sintx Technologies -1,058.60% -366.49% -115.04% PetVivo -902.82% -4,813.07% -281.78%

Do analysts prefer SINT or POAI?

Sintx Technologies currently has a consensus target price of $11.00, suggesting a potential upside of 391.07%. Given Sintx Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sintx Technologies is more favorable than Predictive Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sintx Technologies 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Sintx Technologies (SINT) Competitors

$2.24 +0.16 (+7.69%)

Closing price 04:00 PM Eastern

Extended Trading

$2.19 -0.05 (-2.05%)

As of 07:52 PM Eastern

Compare

SINT vs. MLSS, NMTC, CTSO, PETV, and POAI

Should you buy Sintx Technologies stock or one of its competitors? MarketBeat compares Sintx Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sintx Technologies include Milestone Scientific (MLSS), NeuroOne Medical Technologies (NMTC), Cytosorbents (CTSO), PetVivo (PETV), and Predictive Oncology (POAI). These companies are all part of the "medical equipment" industry.

How does Sintx Technologies compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Milestone Scientific has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

In the previous week, Sintx Technologies had 1 more articles in the media than Milestone Scientific. MarketBeat recorded 2 mentions for Sintx Technologies and 1 mentions for Milestone Scientific. Sintx Technologies' average media sentiment score of 0.93 beat Milestone Scientific's score of 0.67 indicating that Sintx Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Milestone Scientific	Positive
Sintx Technologies	Positive

Milestone Scientific has a net margin of -52.01% compared to Sintx Technologies' net margin of -1,058.60%. Milestone Scientific's return on equity of -60.26% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Scientific	-52.01%	-60.26%	-40.23%
Sintx Technologies	-1,058.60%	-366.49%	-115.04%

Milestone Scientific currently has a consensus target price of $1.00, suggesting a potential upside of 156.41%. Sintx Technologies has a consensus target price of $11.00, suggesting a potential upside of 391.07%. Given Sintx Technologies' higher possible upside, analysts clearly believe Sintx Technologies is more favorable than Milestone Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

5.8% of Milestone Scientific shares are owned by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are owned by institutional investors. 12.5% of Milestone Scientific shares are owned by company insiders. Comparatively, 4.1% of Sintx Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Milestone Scientific has higher revenue and earnings than Sintx Technologies. Milestone Scientific is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Scientific	$8.90M	3.86	-$6.93M	-$0.05	N/A
Sintx Technologies	$1.02M	9.49	-$10.36M	-$5.07	N/A

Summary

Milestone Scientific beats Sintx Technologies on 9 of the 16 factors compared between the two stocks.

How does Sintx Technologies compare to NeuroOne Medical Technologies?

Sintx Technologies (NASDAQ:SINT) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Sintx Technologies presently has a consensus price target of $11.00, indicating a potential upside of 391.07%. NeuroOne Medical Technologies has a consensus price target of $11.67, indicating a potential upside of 236.22%. Given Sintx Technologies' higher probable upside, equities research analysts plainly believe Sintx Technologies is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Sintx Technologies has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

In the previous week, Sintx Technologies and Sintx Technologies both had 2 articles in the media. Sintx Technologies' average media sentiment score of 0.93 beat NeuroOne Medical Technologies' score of 0.29 indicating that Sintx Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sintx Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroOne Medical Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NeuroOne Medical Technologies has a net margin of -68.35% compared to Sintx Technologies' net margin of -1,058.60%. NeuroOne Medical Technologies' return on equity of -98.33% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-1,058.60%	-366.49%	-115.04%
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%

NeuroOne Medical Technologies has higher revenue and earnings than Sintx Technologies. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02M	9.49	-$10.36M	-$5.07	N/A
NeuroOne Medical Technologies	$12.10M	2.47	-$3.61M	-$0.85	N/A

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

NeuroOne Medical Technologies beats Sintx Technologies on 9 of the 15 factors compared between the two stocks.

How does Sintx Technologies compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Sintx Technologies (NASDAQ:SINT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Cytosorbents presently has a consensus target price of $5.38, indicating a potential upside of 999.18%. Sintx Technologies has a consensus target price of $11.00, indicating a potential upside of 391.07%. Given Cytosorbents' higher possible upside, research analysts clearly believe Cytosorbents is more favorable than Sintx Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cytosorbents has higher revenue and earnings than Sintx Technologies. Cytosorbents is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.83	-$8.20M	-$0.19	N/A
Sintx Technologies	$1.02M	9.49	-$10.36M	-$5.07	N/A

Cytosorbents has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Sintx Technologies has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

In the previous week, Cytosorbents and Cytosorbents both had 2 articles in the media. Sintx Technologies' average media sentiment score of 0.93 beat Cytosorbents' score of 0.30 indicating that Sintx Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sintx Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytosorbents has a net margin of -31.85% compared to Sintx Technologies' net margin of -1,058.60%. Cytosorbents' return on equity of -235.57% beat Sintx Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Sintx Technologies	-1,058.60%	-366.49%	-115.04%

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are held by institutional investors. 7.3% of Cytosorbents shares are held by insiders. Comparatively, 4.1% of Sintx Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Cytosorbents beats Sintx Technologies on 10 of the 15 factors compared between the two stocks.

How does Sintx Technologies compare to PetVivo?

Sintx Technologies (NASDAQ:SINT) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

PetVivo has a net margin of -902.82% compared to Sintx Technologies' net margin of -1,058.60%. Sintx Technologies' return on equity of -366.49% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-1,058.60%	-366.49%	-115.04%
PetVivo	-902.82%	-4,813.07%	-281.78%

Sintx Technologies has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, PetVivo has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

Sintx Technologies has higher earnings, but lower revenue than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02M	9.49	-$10.36M	-$5.07	N/A
PetVivo	$1.05M	24.94	-$10.95M	-$0.38	N/A

Sintx Technologies currently has a consensus target price of $11.00, indicating a potential upside of 391.07%. Given Sintx Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Sintx Technologies is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 24.5% of PetVivo shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by company insiders. Comparatively, 10.8% of PetVivo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Sintx Technologies had 2 more articles in the media than PetVivo. MarketBeat recorded 2 mentions for Sintx Technologies and 0 mentions for PetVivo. Sintx Technologies' average media sentiment score of 0.93 beat PetVivo's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Sintx Technologies	Positive
PetVivo	Neutral

Summary

Sintx Technologies beats PetVivo on 9 of the 16 factors compared between the two stocks.

How does Sintx Technologies compare to Predictive Oncology?

Sintx Technologies (NASDAQ:SINT) and Predictive Oncology (NASDAQ:POAI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Sintx Technologies has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

In the previous week, Sintx Technologies had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for Sintx Technologies and 0 mentions for Predictive Oncology. Sintx Technologies' average media sentiment score of 0.93 beat Predictive Oncology's score of 0.00 indicating that Sintx Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Sintx Technologies	Positive
Predictive Oncology	Neutral

Sintx Technologies has higher earnings, but lower revenue than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.02M	9.49	-$10.36M	-$5.07	N/A
Predictive Oncology	$1.66M	17.86	-$12.66M	-$13.50	N/A

Sintx Technologies has a net margin of -1,058.60% compared to Predictive Oncology's net margin of -5,065.23%. Sintx Technologies' return on equity of -366.49% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-1,058.60%	-366.49%	-115.04%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Sintx Technologies currently has a consensus target price of $11.00, suggesting a potential upside of 391.07%. Given Sintx Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sintx Technologies is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

18.4% of Sintx Technologies shares are owned by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are owned by institutional investors. 4.1% of Sintx Technologies shares are owned by company insiders. Comparatively, 1.2% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Sintx Technologies beats Predictive Oncology on 13 of the 16 factors compared between the two stocks.

Get Sintx Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SINT vs. The Competition

Export

Metric	Sintx Technologies	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.98M	$7.25B	$6.47B	$12.54B
Dividend Yield	N/A	1.23%	2.69%	5.22%
P/E Ratio	-0.44	45.06	22.39	24.18
Price / Sales	9.49	74.02	520.79	112.26
Price / Cash	N/A	24.22	41.34	57.13
Price / Book	2.80	7.15	9.84	6.72
Net Income	-$10.36M	$159.22M	$3.57B	$337.19M
7 Day Performance	-2.18%	0.91%	-1.16%	0.48%
1 Month Performance	-7.05%	3.99%	3.85%	5.07%
1 Year Performance	-18.84%	1.56%	27.40%	34.25%

Sintx Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SINT Sintx Technologies	3.0465 of 5 stars	$2.24 +7.7%	$11.00 +391.1%	-24.6%	$8.98M	$1.02M	N/A	40	News Coverage Gap Down High Trading Volume
MLSS Milestone Scientific	1.5934 of 5 stars	$0.39 +1.6%	$1.00 +155.1%	-58.5%	$34.53M	$8.90M	N/A	30	Gap Down
NMTC NeuroOne Medical Technologies	2.4531 of 5 stars	$3.56 -4.3%	$11.67 +227.7%	+0.1%	$32.07M	$12.10M	N/A	20	Short Interest Increase
CTSO Cytosorbents	1.8095 of 5 stars	$0.48 +2.6%	$5.38 +1,019.8%	-44.1%	$29.38M	$37.06M	N/A	220	News Coverage
PETV PetVivo	N/A	$0.80 +14.3%	N/A	+4.6%	$25.50M	$1.05M	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SINT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sintx Technologies (SINT) Competitors

SINT vs. MLSS, NMTC, CTSO, PETV, and POAI

How does Sintx Technologies compare to Milestone Scientific?

Summary

How does Sintx Technologies compare to NeuroOne Medical Technologies?

Summary

How does Sintx Technologies compare to Cytosorbents?

Summary

How does Sintx Technologies compare to PetVivo?

Summary

How does Sintx Technologies compare to Predictive Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SINT vs. The Competition

Sintx Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sintx Technologies (SINT) Competitors

SINT vs. MLSS, NMTC, CTSO, PETV, and POAI

How does Sintx Technologies compare to Milestone Scientific?

Which has more risk & volatility, MLSS or SINT?

Does the media refer more to MLSS or SINT?

Is MLSS or SINT more profitable?

Do analysts prefer MLSS or SINT?

Do institutionals & insiders hold more shares of MLSS or SINT?

Which has preferable valuation and earnings, MLSS or SINT?

Summary

How does Sintx Technologies compare to NeuroOne Medical Technologies?

Do analysts rate SINT or NMTC?

Which has more risk and volatility, SINT or NMTC?

Does the media favor SINT or NMTC?

Is SINT or NMTC more profitable?

Which has preferable earnings and valuation, SINT or NMTC?

Do insiders and institutionals believe in SINT or NMTC?

Summary

How does Sintx Technologies compare to Cytosorbents?

Do analysts recommend CTSO or SINT?

Which has better valuation & earnings, CTSO or SINT?

Which has more risk and volatility, CTSO or SINT?

Does the media favor CTSO or SINT?

Is CTSO or SINT more profitable?

Do institutionals & insiders believe in CTSO or SINT?

Summary

How does Sintx Technologies compare to PetVivo?

Is SINT or PETV more profitable?

Which has more volatility & risk, SINT or PETV?

Which has preferable earnings & valuation, SINT or PETV?

Do analysts rate SINT or PETV?

Do institutionals and insiders have more ownership in SINT or PETV?

Does the media prefer SINT or PETV?

Summary

How does Sintx Technologies compare to Predictive Oncology?

Which has more volatility & risk, SINT or POAI?

Does the media prefer SINT or POAI?

Which has stronger earnings and valuation, SINT or POAI?

Is SINT or POAI more profitable?

Do analysts prefer SINT or POAI?

Do insiders & institutionals hold more shares of SINT or POAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SINT vs. The Competition

Sintx Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools